Red blood cell biomimetic nanoparticle with anti-inflammatory, anti-oxidative and hypolipidemia effect ameliorated atherosclerosis therapy

Liang, Xiaoyu; Li, Huiyang; Zhang, Aiai; Tian, Xinxin; Guo, Haoyang; Zhang, Hailing; Yang, Jing; Zeng, Yong

doi:10.1016/j.nano.2022.102519

Cited by 20 publications

(9 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen and Schilperoort reviewed macrophage-targeted nanoparticles and nanomedicines designed and applied in the diagnosis and treatment of AS [ 27 ]. Liang et al reported a red blood cell biomimetic nanoparticle for AS treatment that exerted anti-inflammatory, antioxidative, and hypolipidemic effects [ 28 ]. In addition, Chyu also studied an apoB-100 peptide-linked nanoparticle to activate immunization against AS progression [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Targeted Diagnosis, Therapeutic Monitoring, and Assessment of Atherosclerosis Based on Mesoporous Silica Nanoparticles Coated with cRGD-Platelets

Zhang

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Objective. The off-target effects and severe side effects of PPARα and LXRα agonists greatly limit their application in atherosclerosis (AS). Therefore, this study intended to use mesoporous silica nanoparticles as carriers to generate MnO nanoparticles in situ with T1WI-MRI in mesoporous pores and simultaneously load PPARα and LXRα agonists. Afterward, cRGD-chelated platelet membranes can be used for coating to construct a new nanotheranostic agent. Methods. cRGD-platelet@MnO/MSN@PPARα/LXRα nanoparticles were synthesized by a chemical method. Dynamic light scattering (DLS) was utilized to detect the size distribution and polydispersity index (PDI) of the nanoparticles. The safety of the nanoparticles was detected by CCK8 in vitro and HE staining and kidney function in vivo. Cell apoptosis was detected by flow cytometry detection and TUNEL staining. Oxidative stress responses (ROS, SOD, MDA, and NOX levels) were tested via a DCFH-DA assay and commercial kits. Immunofluorescence and phagocytosis experiments were used to detect the targeting of nanoparticles. Magnetic resonance imaging (MRI) was used to detect the imaging performance of cRGD-platelet@MnO/MSN@PPARα/LXRα nanoparticles. Using western blotting, the expression changes in LXRα and ABCA1 were identified. Results. cRGD-platelet@MnO/MSN@PPARα/LXRα nanoparticles were successfully established, with a particle size of approximately 150 nm and PDI less than 0.3, and showed high safety both in vitro and in vivo. cRGD-platelet@MnO/MSN@PPARα/LXRα nanoparticles showed good targeting properties and better MRI imaging performance in AS. cRGD-platelet@MnO/MSN@PPARα/LXRα nanoparticles showed better antioxidative capacities, MRI imaging performance, and diagnostic and therapeutic effects on AS by regulating the expression of LXRα and ABCA1. Conclusion. In the present study, cRGD-platelet@MnO/MSN@PPARα/LXRα nanoparticles with high safety and the capacity to target vulnerable plaques of AS were successfully established. They showed better performance on MRI images and treatment effects on AS by promoting cholesterol efflux through the regulation of ABCA1. These findings might address the problems of off-target effects and side effects of nanoparticle-mediated drug delivery, which will enhance the efficiency of AS treatment and provide new ideas for the clinical treatment of AS.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeted Diagnosis, Therapeutic Monitoring, and Assessment of Atherosclerosis Based on Mesoporous Silica Nanoparticles Coated with cRGD-Platelets

Zhang

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…In another study, Liang et al developed biomimetic RBC-cloaked PLGA-based nanoparticles for the controlled delivery of probucol, a compound with anti-inflammatory, antioxidative and hypolipidemic effects. 914 These nanoparticles exhibited sustained drug release kinetics, good biocompatibility and antiinflammatory effects in vitro, and led to delayed blood circulation in vivo, significantly delaying the progression of atherosclerosis.…”

Section: Antimicrobial Therapymentioning

confidence: 99%

Polymeric Nanoparticles for Drug Delivery

Beach,

Nayanathara,

Gao

et al. 2024

Chem. Rev.

View full text Add to dashboard Cite

The recent emergence of nanomedicine has revolutionized the therapeutic landscape and necessitated the creation of more sophisticated drug delivery systems. Polymeric nanoparticles sit at the forefront of numerous promising drug delivery designs, due to their unmatched control over physiochemical properties such as size, shape, architecture, charge, and surface functionality. Furthermore, polymeric nanoparticles have the ability to navigate various biological barriers to precisely target specific sites within the body, encapsulate a diverse range of therapeutic cargo and efficiently release this cargo in response to internal and external stimuli. However, despite these remarkable advantages, the presence of polymeric nanoparticles in wider clinical application is minimal. This review will provide a comprehensive understanding of polymeric nanoparticles as drug delivery vehicles. The biological barriers affecting drug delivery will be outlined first, followed by a comprehensive description of the various nanoparticle designs and preparation methods, beginning with the polymers on which they are based. The review will meticulously explore the current performance of polymeric nanoparticles against a myriad of diseases including cancer, viral and bacterial infections, before finally evaluating the advantages and crucial challenges that will determine their wider clinical potential in the decades to come.

show abstract

“…Hu et al first reported a natural erythrocyte membrane-encapsulated poly (lactic-co-glycolic acid) (PLGA) nanoparticle that significantly prolonged the in vivo circulation time compared to only PLGA and PEGylated PLGA ( Hu et al, 2011 ). Studies have also reported that nanoparticles coated with erythrocyte membranes have significant therapeutic effects in treating thrombosis, atherosclerosis, sepsis, and other vascular diseases ( Wang Y. et al, 2019 ; Ben-Akiva et al, 2020 ; Zhao et al, 2020 ; Liang et al, 2022 ).…”

Section: Intravascular Targeting Nanoparticlesmentioning

confidence: 99%

Advances in nanomaterial-based targeted drug delivery systems

Cheng

Xie

Sun

2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Nanomaterial-based drug delivery systems (NBDDS) are widely used to improve the safety and therapeutic efficacy of encapsulated drugs due to their unique physicochemical and biological properties. By combining therapeutic drugs with nanoparticles using rational targeting pathways, nano-targeted delivery systems were created to overcome the main drawbacks of conventional drug treatment, including insufficient stability and solubility, lack of transmembrane transport, short circulation time, and undesirable toxic effects. Herein, we reviewed the recent developments in different targeting design strategies and therapeutic approaches employing various nanomaterial-based systems. We also discussed the challenges and perspectives of smart systems in precisely targeting different intravascular and extravascular diseases.

show abstract

Red blood cell biomimetic nanoparticle with anti-inflammatory, anti-oxidative and hypolipidemia effect ameliorated atherosclerosis therapy

Cited by 20 publications

References 50 publications

Targeted Diagnosis, Therapeutic Monitoring, and Assessment of Atherosclerosis Based on Mesoporous Silica Nanoparticles Coated with cRGD-Platelets

Targeted Diagnosis, Therapeutic Monitoring, and Assessment of Atherosclerosis Based on Mesoporous Silica Nanoparticles Coated with cRGD-Platelets

Polymeric Nanoparticles for Drug Delivery

Advances in nanomaterial-based targeted drug delivery systems

Contact Info

Product

Resources

About